Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $113 | $97 | $176 | $95 |
| Short-Term Investments | $289 | $284 | $232 | $197 |
| Receivables | $74 | $60 | $64 | $48 |
| Inventory | $4 | $4 | $3 | $3 |
| Other Curr. Assets | $22 | $29 | $6 | $15 |
| Total Curr. Assets | $502 | $474 | $481 | $357 |
| Property Plant & Equip (Net) | $16 | $3 | $3 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $8 | $8 | $8 | $8 |
| Long-Term Investments | $6 | $3 | $3 | $3 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $6 | $6 | $6 |
| Total NC Assets | $33 | $21 | $20 | $20 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $535 | $495 | $501 | $377 |
| Liabilities | – | – | – | – |
| Payables | $41 | $28 | $28 | $28 |
| Short-Term Debt | $0 | $0 | $0 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $76 | $62 | $58 | $52 |
| Total Curr. Liab. | $117 | $90 | $86 | $81 |
| LT Debt | $82 | $72 | $72 | $72 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $82 | $72 | $72 | $72 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $10 | $0 | $0 | $1 |
| Total Liabilities | $199 | $162 | $158 | $152 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$418 | -$406 | -$385 | -$360 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $753 | $738 | $728 | $585 |
| Total Equity | $335 | $333 | $342 | $225 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $535 | $495 | $501 | $377 |
| Net Debt | -$30 | -$24 | -$103 | -$22 |